NCT06158516

A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Changhai Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

pNENs still have a risk of recurrence after radical resection, and the overall recurrence and metastasis rate is as high as 13.7%-36.2% in China. At present, there is no standard adjuvant therapy for pNEN, and prospective studies are still lacking. This study was a randomized, double-blind, placebo-controlled, multicenter clinical trial to explore the efficacy and safety of surufatinib in the adjuvant treatment of pNET, in order to further improve the prognosis of patients and to provide high-quality research evidence for adjuvant therapy.

Conditions

• Pancreatic Neuroendocrine Tumor

Interventions

Type	Name	Description
DRUG	Surufatinib	Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
DRUG	Placebo	Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle

Timeline

• Start date: 2023-11-30
• Primary completion: 2026-11-29
• Completion: 2026-11-29
• First posted: 2023-12-06
• Last updated: 2023-12-06

Locations

1 site across 1 country: China